VERO BEACH, Fla., March 1, 2025 /PRNewswire/ -- QOL Medical, LLC, a ground-breaking rare disease pharmaceutical company, has announced Sucraid® (sacrosidase) Oral Solution has been shown to be 81% ...
The FDA is recommending that clinicians prioritize access to the unapproved lot of Sucraid for patients with severe CSID and for patients with evidence of malnutrition. The Food and Drug ...
ROCKVILLE, Md. The Food and Drug Administration sped up the approval process to allowing changes in the manufacturing of a treatment for congenital sucrase-isomaltase deficiency, the agency said in a ...
The FDA has hit QOL Medical with an untitled letter over emails about Sucraid, accusing the company of creating a misleading impression about the indication for the rare disease drug. FDA officials ...
Sucraid is an oral enzyme replacement therapy of the genetically determined sucrase deficiency. The Food and Drug Administration (FDA) has approved Sucraid ® (sacrosidase) Oral Solution single-use ...
To earn CME related to this news article, click here. March 4, 2009 — The US Food and Drug Administration (FDA) has approved safety labeling revisions to provide additional counseling information for ...
VERO BEACH, Fla., Nov. 20, 2017 /PRNewswire/ -- QOL Medical LLC, a rare-disease pharmaceutical company, today announced their new partnership with US Bioservices as the exclusive Sucraid® specialty ...
LONDON, GREATER LONDON, UNITED KINGDOM, March 14, 2025 /EINPresswire / -- How Has the Sucraid Market Grown in Recent Years? The Sucraid market, which serves as a crucial enzyme replacement therapy for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results